These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 20346038)

  • 1. Giant warts in a kidney transplant patient: regression with sirolimus.
    Kostaki M; Venetz JP; Nseir G; Meylan P; Sahli R; Pascual M; Laffitte E
    Br J Dermatol; 2010 May; 162(5):1148-50. PubMed ID: 20346038
    [No Abstract]   [Full Text] [Related]  

  • 2. Sirolimus-based immunosuppression for treatment of cutaneous warts in kidney transplant recipients.
    Shahidi S; Moeinzadeh F; Mohammadi M; Gholamrezaei A
    Iran J Kidney Dis; 2011 Sep; 5(5):351-3. PubMed ID: 21876315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sirolimus and regression of Kaposi's sarcoma in immunosuppressed transplant patient.
    Pranteda G; Feliziani G; Grimaldi M; Paleologo G; Pranteda G; Melotti F; Camplone G
    J Eur Acad Dermatol Venereol; 2008 Aug; 22(8):1022-3. PubMed ID: 18194240
    [No Abstract]   [Full Text] [Related]  

  • 4. Combined use of sirolimus and voriconazole in renal transplantation: a report of two cases.
    Mathis AS; Shah NK; Friedman GS
    Transplant Proc; 2004 Nov; 36(9):2708-9. PubMed ID: 15621130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conversion to rapamycin in a renal transplant patient with von Hippel-Lindau disease: encouraging results-a case report.
    Henriquez F; Gallego R; Oliva E; Silva D; Vega N
    Transplant Proc; 2008 Nov; 40(9):3115-6. PubMed ID: 19010210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients.
    Sundberg AK; Rohr MS; Hartmann EL; Adams PL; Stratta RJ
    Clin Transplant; 2004; 18 Suppl 12():61-6. PubMed ID: 15217410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sirolimus for Kaposi's sarcoma.
    Wasywich CA; Croxson MC; van Doornum GJ; Coverdale HA; Ruygrok PN
    J Heart Lung Transplant; 2006 Jun; 25(6):726-9. PubMed ID: 16730579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sirolimus inhibits oxidative burst activity in transplant recipients.
    Gee I; Trull AK; Charman SC; Alexander GJ
    Transplantation; 2003 Dec; 76(12):1766-8. PubMed ID: 14688530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunosuppressive drugs and the risk of cancer after organ transplantation.
    Dantal J; Soulillou JP
    N Engl J Med; 2005 Mar; 352(13):1371-3. PubMed ID: 15800234
    [No Abstract]   [Full Text] [Related]  

  • 10. A novel immunosuppressive agent, sirolimus, in the treatment of Kaposi's sarcoma in a renal transplant recipient.
    Yilmaz R; Akoglu H; Kirkpantur A; Kilickap S; Arici M; Altun B; Aki T; Erdem Y; Yasavul U; Turgan C
    Ren Fail; 2007; 29(1):103-5. PubMed ID: 17365918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion.
    Sayin B; Karakayali H; Colak T; Sevmis S; Pehlivan S; Demirhan B; Haberal M
    Transplant Proc; 2009 Sep; 41(7):2789-93. PubMed ID: 19765436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complete regression of visceral Kaposi's sarcoma after conversion to sirolimus.
    Mohsin N; Budruddin M; Pakkyara A; Darweesh A; Nayyer M; Amitabh J; Daar AS
    Exp Clin Transplant; 2005 Dec; 3(2):366-9. PubMed ID: 16417445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sirolimus for solid organ transplantation in children.
    Gupta P; Kaufman S; Fishbein TM
    Pediatr Transplant; 2005 Jun; 9(3):269-76. PubMed ID: 15910380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conversion from calcineurin inhibitors to sirolimus in kidney transplant patients reduces the urinary transforming growth factor-beta1 concentration.
    Saurina A; Campistol JM; Lario S; Oppenheimer F; Diekmann F
    Transplant Proc; 2007 Sep; 39(7):2138-41. PubMed ID: 17889117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regression of post-transplant Kaposi's sarcoma using sirolimus.
    Kolhe N; Mamode N; Van der Walt J; Pattison J
    Int J Clin Pract; 2006 Nov; 60(11):1509-12. PubMed ID: 16787440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Choice of immunosuppressants and the risk of warts in renal transplant recipients.
    Dicle O; Parmaksizoglu B; Gurkan A; Tuncer M; Demirbas A; Yilmaz E
    Acta Derm Venereol; 2008; 88(3):294-5. PubMed ID: 18480941
    [No Abstract]   [Full Text] [Related]  

  • 17. Sirolimus (rapamycin) reduces the incidence of acute rejection episodes in renal transplantation: an initial experience in Taiwan.
    Liu KL; Chu SH; Chiang YJ; Wu CT; Chen Y
    Transplant Proc; 2004 Sep; 36(7):2051-2. PubMed ID: 15518742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complete regression of cutaneous B-cell lymphoma in a renal transplant patient after conversion from cyclosporin to sirolimus.
    Mohsin N; Budruddin M; Kamble P; Khalil M; Pakkyarra A; Jha A; Mohammed E; Ahmed H; Ahmed J; Thomas S; Campistol JM; Daar A
    Transplant Proc; 2007 May; 39(4):1267-71. PubMed ID: 17524950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is sirolimus a nephrotoxic drug? A report of five cases.
    Sabry AA; Elagroudy AE; El-dahshan KF; El-Rahim MA; Sobh MA
    Transplant Proc; 2007 Jun; 39(5):1406-9. PubMed ID: 17580149
    [No Abstract]   [Full Text] [Related]  

  • 20. [Immunosuppression with sirolimus so donor kidneys survive longer].
    MMW Fortschr Med; 2004 Aug; 146(31-32):46-7. PubMed ID: 15529711
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.